Mirdametinib

SKU: orb1300996

Description

Mirdametinib

Research Area

Cell Biology, Signal Transduction

Key Properties

• CAS Number: 391210-10-9
• MW: 482.19
• Purity: 99.11%
• Formula: C₁₆H₁₄F₃IN₂O₄
• SMILES: OC[C@@H](O)CONC(=O)C1=CC=C(F)C(F)=C1NC1=CC=C(I)C=C1F
• Target: Autophagy,Apoptosis,MEK
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (10.37 mM);H2O:Insoluble;DMSO:50 mg/mL (103.69 mM)

Bioactivity

• Target IC50:
  MEK1:1 nM (Ki)|MEK2:1 nM (Ki)|MEK:0.33 nM (cell free)
• In Vivo:
  METHODS: To assay antitumor activity in vivo Mirdametinib (20-25 mg/kg, 80 mmol/L citric buffer (pH 7)) was administered by gavage to Athymic Ncr-nu/nu mice harboring PTC tumors K2 or TPC-1 five times per week for three weeks. Results: Mirdametinib completely inhibited tumor growth in mice inoculated with PTC cells K2 harboring BRAF mutations and significantly reduced tumor growth in mice inoculated with PTC cells TPC-1 harboring RET/PTC1 rearrangements. METHODS: To assay anti-tumor activity in vivo Mirdametinib (1.6-25 mg/kg, 0.5% hydroxypropylmethylcellulose + 0.2% Tween 80 in water) was administered orally to mice bearing mouse colorectal cancer tumor CT26 once daily for fourteen days. Results: Mirdametinib significantly inhibited pERK levels in tumors.
• In Vitro:
  METHODS: Eleven human melanoma cell lines were treated with Mirdametinib (0.1-1000 nM) for 72 h, and cell counts were determined usin the trypan blue exclusion test. Results: Mirdametinib IC50 20-50 nM) effectively inhibite the growth of human melanoma cell lines with BRAF mutations (M14/A375P/A375M/A375SM/ME10538/ME4686/JR8) or without BRAF mutations (ME4405/ME13923). ME8959 both have wild-type BRAF and are slightly more resistant to Mirdametinib-mediated growth Inhibition IC50 100 nM). METHODS: Papillary thyroid carcinoma (PTC) cell lines K2 and TPC-1 were treated with Mirdametinib (0.1-1000 nMol/L) for 1-96 h. Target protein expression levels were detected by Western Blot. Results: Mirdametinib effectively inhibite the phosphorylation of ERK1/2 in various PTC cell lines.
• Cell Research:
  A cell death detection enzyme-linked immunosorbent assay was used pe the manufacturer's instructions. Briefly, 4 × 10^4 cells were plated in 24-well plates in triplicat the day before treatment. PTC cells were treated with 0.1 μMol/L PD0325901 for 96 hours. Cells treated with 1 μMol/L staurosporine served as positive controls for apoptosis. A the end of treatment, cells were lysed usin the lysis buffer provided in the kit for 30 minutes at room temperature and then centrifuged in 24-well plates. Lysates (20 μL of supernatant) were transferred to streptavidin-coated wells and incubated for 2 hours at room temperature with two antibodies (biotin-labeled anti-histone antibody and peroxidase-conjugated anti-DNA antibody). Afte the wells were washed three times the Samples were incubated with peroxidase substratee (ABTS) an the amount of colored product was determined spectrophotometrically at 405 nM the background was measured at 490 nM.
• Animal Research:
  Athymic Ncr-nu/nu mice were obtained fro the National Cancer Institute at ages 6 to 8 weeks and housed for at least 1 week after arrival. Mice (10–14 per group) were anesthetized s.c. With a cocktail (100 μL/10 g body weight of 10 mg mL ketamine and 1 mg mL xylazine). K2 and TPC-1 cells stably infected with a retrovirus expressing luciferase (5 × 105 cells in 5 μL RPMI1640 medium) were inoculated int the thyroid g and an the mice were monitored weekly for tumor growth by Xenogen (IVIS 200 imaging system) using Living Image 3.0 software. One week after inoculation, PD0325901 was dissolved in 80 mmol/L citric buffer (pH 7) by sonication and given to mice daily by oral gavage (20–25 mg/kg) for 3 weeks (5 consecutive days/week). Mice were sacrificed only due to tumor burden or loss of 20% of body weight. Tumor sizes were measured with calipers and tumor volume (V) was calculated b the formula (V = length × width × depth). Control mice were given 80 mmol/L citric buffer (pH 7) alone. All in vivo experiments were done at least twice.

Storage & Handling

• Storage: keep away from direct sunlight,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Disclaimer: For research use only

Alternative Names

Autophagy, Apoptosis, inhibit, Mitogen-activated protein kinase kinase, Mirdametinib, PD325901, PD-325901, PD0325901, PD-0325901, PD 0325901, PD 325901, Inhibitor, MAP2K, MAPKK, MEK

Compound Identifiers

PubChem CID

9826528